Popular Articles

Journal Of Clinical Oncology Publishes Study Demonstrating Improvement In Overall Response And Progression-Free Survival-Chronic Lymphocytic Leukemia
Cephalon, Inc. (Nasdaq: CEPH) announced yesterday that the Journal of Clinical Oncology has published data from a pivotal phase 3 study demonstrating that TREANDA® (bendamustine HCl) for Injection improved clinical outcomes when compared to chlorambucil in patients with chronic lymphocytic leukemia (CLL). Results of this study were the basis of the March 2008 U.S. Food and Drug Administration (FDA) approval of TREANDA for CLL, the first agent approved by the FDA for this disease since 2001. According to the American Cancer Society, there will be more than 15,000 new cases of CLL diagnosed in 2009 alone. The study results were published online today and will also appear in the print edition later this year.
buy viagra
Bariatric Surgery Patients Have 67 Percent Lower Chance Of Complications At Top Hospitals: Study
The HealthGrades Fourth Annual Bariatric Surgery Trends in American Hospitals Study released today identifies 88 hospitals as "best" performers (five-star rated), with mortality rates, complication rates and patient lengths of stay that are dramatically lower than poorly rated hospitals.
News of the day
Viral Meningitis Warning For This Bank Holiday Weekend And Summer
With temperatures predicted to soar this bank holiday weekend and summer, the UK"s longest established meningitis charity - the Meningitis Trust - is urging people to be aware of the signs and symptoms of the disease, as cases are known to peak during hot summers.
Cardiovascular

Too Many Ways To Say 'It Hurts'

There are at least 100 ways to say, "It hurts!" And that is the problem. David Cella is on mission -- backed by nearly $10 million in National Institutes of Health funds -- to revolutionize the language of pain, as well as fatigue, depression and anxiety. These are some of the important symptoms researchers measure when they try to figure out if a medical treatment improves the quality of life for a patient with a chronic disease. Are they in too much pain to unload groceries from the car? Are they too tired or depressed to go out to lunch with a friend? The answers are vital for researchers to know if new treatments are useful or useless. But the glitch is every group of researchers asks patients different questions to measure their symptoms. Thus, one group"s measurement of severe pain or fatigue or depression may be different than another"s. Because researchers aren"t speaking a common language, doctors and other health care providers can"t compare the results across studies to decide which is the best approach. Instead, study results remain separate puzzle pieces that never fit together into a whole picture. "Can you imagine if a doctor wanted to check your hemoglobin and there weren"t any numbers to measure whether it was normal?" asked Cella , professor and chair of the new department of medical social sciences at Northwestern University Feinberg School of Medicine and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. "When you say a patient"s hemoglobin is 11, everybody knows what it means, but nobody knows what a pain of 36 means or a fatigue of 32 because we don"t use common measures." That"s about to change. Cella is leading a far-reaching new national project that establishes a common scientific vocabulary. In August, he and colleagues from six other institutions and the NIH will release a set of free publicly available computerized tests for researchers to measure pain, fatigue, depression, anxiety and physical and social functioning. Now there will be a pain measurement of 75, for example, that will mean the same thing to every doctor and scientist. The new project is called Patient-Reported Outcome Measurement Information System (PROMIS). More than 1,000 researchers have already registered to try the new tools. Cella"s project addresses President Obama"s call for greater accountability in medical treatment. "In order to have a system that works that way you need a consistent measure of outcomes that people can understand and relate to," Cella said. "That"s what we have developed." The lack of a common vocabulary has hurt research, Cella noted. ""It"s a Tower of Babel, a hodge-podge of language. It"s a big problem because you can"t migrate the results of one study to a broader understanding," he said. "We keep having to learn the same things over and over. We are not building on a foundation of knowledge." Not only have Cella and his team created a new language and tool for researchers, but the PROMIS project also represents a shift in the way researchers evaluate the benefits of treatments. The goal is not just to help people live longer but also live better. X-rays, CT scans and lab tests may have minimal relevance to the day-to-day functioning of patients with chronic diseases. "We help measure directly if people are living better by asking them," Cella said. "Sometimes it"s as simple as asking, "Do you think this treatment has made your life better?" That question is surprisingly absent from many studies." Marla Paul Northwestern University


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):